Improving L-dopa treatment for Parkinson's disease by altering gut bacteria
Modifying the microbiome to enhance L-dopa therapy in Parkinson’s disease
This study is looking at how changing the bacteria in your gut might help make L-dopa work better for people with Parkinson's disease, so you can manage your symptoms more effectively and possibly experience fewer side effects.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Medical College of Wisconsin NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project ID | NIH-11074696 on NIH RePORTER |
What this research studies
This research investigates how modifying the gut microbiome can enhance the effectiveness of L-dopa therapy in patients with Parkinson's disease. The approach focuses on understanding the role of specific gut bacteria that metabolize L-dopa, potentially leading to better management of motor symptoms. By targeting the bacteria responsible for converting L-dopa into dopamine, which cannot cross the blood-brain barrier, the study aims to improve treatment outcomes and reduce side effects. Patients may be involved in trials that explore dietary or probiotic interventions to optimize their L-dopa therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Parkinson's disease who are currently receiving or are eligible for L-dopa therapy.
Not a fit: Patients with Parkinson's disease who are not on L-dopa therapy or those with contraindications to L-dopa may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective L-dopa treatment, improving motor function and quality of life for Parkinson's disease patients.
How similar studies have performed: Previous research has shown promising results in modifying the gut microbiome to enhance drug efficacy, suggesting potential success for this novel approach.
Where this research is happening
Milwaukee, United States
- Medical College of Wisconsin — Milwaukee, United States (Active)
Researchers
- Principal investigator: Feix, Jimmy — Medical College of Wisconsin
- Study coordinator: Feix, Jimmy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.